[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Chen CH, Chao KC, Wang PH: Advanced cervical squamous cell carcinoma with skin metastasis. Taiwan J Obstet Gynecol; 2007 Sep;46(3):264-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced cervical squamous cell carcinoma with skin metastasis.
  • CASE REPORT: A 72-year-old woman was diagnosed with squamous cell carcinoma of the cervix (FIGO stage, IIB), which was treated with concurrent chemoradiation.
  • After treatment, she was followed up regularly, without evidence of disease.
  • Excision biopsy was performed and showed metastatic carcinoma, favoring a squamous cell type.
  • The patient then underwent a series of imaging examinations, including magnetic resonance imaging of the pelvis and computed tomography of the chest, and a whole body bone scan showed disseminated diseases involving the lung and bone.
  • Palliative chemotherapy was prescribed, and the skin lesions responded relatively well, but disease involving the vital organs still progressed during treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962107.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Younes RN, Deutsch F, Badra C, Gross J, Haddad F, Deheinzelin D: Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution. Rev Hosp Clin Fac Med Sao Paulo; 2004 Jun;59(3):119-27
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution.
  • OBJECTIVE: To analyze surgical and pathological parameters and outcome and prognostic factors of patients with nonsmall cell lung cancer (NSCLC) who were admitted to a single institution, as well as to correlate these findings to the current staging system.
  • Following staging, a multidisciplinary team decision on adequate management was established.
  • Variables included in this analysis were age, gender, histology, Karnofsky index, weight loss, clinical stage, surgical stage, chemotherapy, radiotherapy, and survival rates.
  • The distribution of histologic type was squamous cell carcinoma 51.8%, adenocarcinoma 43.1%, and undifferentiated large cell carcinoma 5.1%.
  • Clinical staging was IA 3.8%, IB 9.2%, IIA 1.4%, IIB 8.1%, IIIA 20.9%, IIIB 22.4%, IV 30.9%.
  • Surgical stage distribution was IA 25.3%, IB 1.4%, IIB 17.1%, IIIA 16.1%, IIIB 20.3%, IV 11.5%.
  • Chemotherapy and radiotherapy were considered therapeutic options in 43% and 72%, respectively.
  • The overall 5-year survival rate of nonsmall cell lung cancer patients in our study was 28%.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15286831.001).
  • [ISSN] 0041-8781
  • [Journal-full-title] Revista do Hospital das Clínicas
  • [ISO-abbreviation] Rev Hosp Clin Fac Med Sao Paulo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of esophagus: report of 9 cases and review of literature.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • Two patients had a stage IIa disease, five had a stage IIb disease, and the other two had a stage III disease of International Union Contrele Cancer (UICC).
  • Three of the nine resected specimens showed foci of squamous cell carcinoma in situ.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


Advertisement
4. Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F: Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg; 2008 May;33(5):829-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
  • INTRODUCTION: Optimal preoperative treatment of stage IIB (Pancoast)/III non-small cell lung cancer (NSCLC) remains undetermined and a subject of controversy.
  • The goal of our study is to confirm feasibility and pathological response rates after induction chemoradiation (CRT) in our community-based treatment center.
  • Induction treatment comprised 3D conformal 4500 cGy radiotherapy delivered to the primary tumor and pathologic hilar and/or mediastinal lymph nodes on CT scan with an extra-margin of 1-1.5 cm.
  • Concurrent chemotherapy regimen was cisplatinum 20mg/m2 d1-d5 and etoposide 50mg/m2 d1-d5, d1-5 d29-33.
  • Inoperable pts were referred for a 20-25 Gy boost +/-1 extra-cycle of cisplatinum+etoposide.
  • RESULTS: From 1996 to 2005, 107 pts were initially selected for treatment and received induction chemoradiation (stage IIB-Pancoast 18, IIIA 58 and IIIB 31, squamous cell carcinoma 48%, adenocarcinoma 44%, large-cell undifferentiated carcinoma 14%).
  • During the 3-month postoperative time, five patients (6.9%) died, four after pneumonectomy (right 3, left 1).
  • Median follow-up time was 22.3 months (survivors: 36.8 months), 2-year and 3-year overall survival rates were 55% and 40%, respectively (median=26.7 months) for all the intention-to-treat population (n=107), 62% and 51% (median=36.5 months) for 71 resected pts, 41% and 16% for 36 non-resected pts (median=19.1 months).
  • CONCLUSION: Surgery was feasible after induction chemoradiation, particularly lobectomy in PS 0-1, stage IIB (Pancoast)/III NSCLC pts but pneumonectomy carries a high risk of postoperative death (particularly, right pneumonectomy).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Lung Neoplasms / drug therapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pneumonectomy. Proportional Hazards Models. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367406.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Sofikerim M, Gülmez I, Tokat F, Er O, Gülmez I: Epidermoid carcinoma of the lung with isolated penile metastasis. Can J Urol; 2007 Aug;14(4):3643-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid carcinoma of the lung with isolated penile metastasis.
  • We report a case of epidermoid-cell carcinoma of the lung that developed a metastatic lesion in the penis.
  • He had a left pneumectomy and was diagnosed with epidermoid carcinoma of the lung at stage IIB (T2N1M0).
  • He was started on an adjuvant chemotherapy protocol consisting of cisplatin and paclitaxel.
  • A fine-needle aspiration biopsy of the penile mass revealed epidermoid carcinoma that was consistent with lung cancer.
  • The patient was considered to have penile metastasis from epidermoid carcinoma of the lung.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lung Neoplasms / pathology. Penile Neoplasms / secondary

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17784986.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


6. Katsuragi N, Shiraishi Y, Kita H, Hashizume M, Miyasaka Y, Tanaka S: [21-year-old man with squamous cell carcinoma of the lung]. Kyobu Geka; 2007 Jul;60(7):529-32
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [21-year-old man with squamous cell carcinoma of the lung].
  • Lung cancer among people in their twenties is rare and accounts for only 0.1-0.4% of all cases.
  • We describe a case of squamous cell carcinoma of the lung in a 21-year-old man.
  • Computed tomography also showed a 3 cm hilar lymph node.
  • Transbronchial biopsy revealed poorly differentiated squamous cell carcinoma of the lung.
  • Clinical diagnosis was T2N1M0, stage IIB lung cancer.
  • Pathological diagnosis was T2N2M0, stage IIIA lung cancer.
  • He received 3 rounds of chemotherapy with cisplatin and docetaxel and irradiation to the right hilum and mediastinum at a total dose of 60 Gy in 30 fractions.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Male. Pneumonectomy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642212.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Jiménez C, Manrique A, Marqués E, Ortega P, Loinaz C, Gómez R, Meneu JC, Abradelo M, Moreno A, López A, Moreno E: Incidence and risk factors for the development of lung tumors after liver transplantation. Transpl Int; 2007 Jan;20(1):57-63
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors for the development of lung tumors after liver transplantation.
  • Tobacco and immunosuppression are risk factors for developing upper aerodigestive and lung tumors after transplantation.
  • The aim is to analyze the incidence, clinical characteristics, risk factors, and outcome of patients who develop lung malignancies after OLT.
  • Incidence of lung cancer was 2.1% (15 patients): 4.3% (12 patients) in the alcoholic group and 0.7% (three patients) in the nonalcoholic group (P < 0.001).
  • Mean time from OLT to tumor diagnosis was 86 months.
  • Squamous cell carcinoma was diagnosed in nine patients, large cell carcinoma in three, adenocarcinoma in two, and broncoalveolar in one.
  • Tumor staging: 10 patients at stage IV; three at stage IIIB; and two at stage IIB.
  • Tumor resection was performed in one patient, and three also received chemotherapy.
  • There is a higher risk of lung cancer in smoker patients who have undergone OLT for AC, and have a very poor prognosis because tumors are diagnosed at advanced stages.
  • [MeSH-major] Liver Transplantation / adverse effects. Lung Neoplasms / epidemiology. Postoperative Complications / epidemiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Transpl Int. 2007 Feb;20(2):201. Ortegz, Patricia [corrected to Ortega, Patricia]
  • (PMID = 17181654.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK: Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. J Thorac Cardiovasc Surg; 2003 Nov;126(5):1603-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.
  • The combination of paclitaxel and carboplatin has been shown to be a well-tolerated and safe regimen in non-small cell lung cancer.
  • The objective of this study was to determine the efficacy of preoperative paclitaxel and carboplatin in patients with carcinoma of the esophagus.
  • Patients with stage I disease and those with visceral metastases were excluded.
  • All underwent preoperative computed tomography scanning and endosonography for staging.
  • Preoperative staging showed: stage IIA, 6 patients; stage IIB, 1 patient; and stage III, 19 patients.
  • All patients completed their preoperative chemotherapy.
  • There was no unexpected chemotherapy-related toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / mortality. Paclitaxel / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Analysis of Variance. Biopsy, Needle. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Esophagectomy / methods. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Pilot Projects. Preoperative Care / methods. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666040.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Taylor NA, Liao ZX, Stevens C, Walsh G, Roth J, Putnam J Jr, Fossella F, Allen P, Cox JD, Komaki R: Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. Int J Radiat Oncol Biol Phys; 2003 Jul 1;56(3):616-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery.
  • PURPOSE: To determine the effectiveness of postoperative radiotherapy (RT) in patients with Stage IIB and Stage IIIA non-small-cell lung cancer (NSCLC) treated with induction chemotherapy followed by surgery.
  • METHODS AND MATERIALS: We retrospectively reviewed the treatment records of 98 patients (58 men and 40 women; median age 61 years, range 31-91) with Stage IIB and Stage IIIA NSCLC who were treated with induction chemotherapy followed by surgery at our institution between January 1990 and December 2000.
  • Patients were grouped by treatment (chemotherapy/surgery alone vs. chemotherapy/surgery/RT), by disease stage and nodal classification.
  • RESULTS: Of the 98 patients, 40 had Stage IIB and 58 had Stage IIIA.
  • The clinical disease stage and N stage were significantly greater in those patients who underwent RT than in those who did not; however, no statistically significant differences were identified in the additional characteristics between those receiving and not receiving RT within each stage or nodal group.
  • The overall 5-year actuarial LC rate was 81% in the RT group and 54% in the chemotherapy/surgery-alone group (p = 0.07).
  • Postoperative RT significantly improved the 5-year LC rate in patients with Stage IIIA disease (from 35% to 82%, p = 0.01).
  • Postoperative RT did not significantly improve the 5-year OS rate (30% with RT vs. 49% without) for all patients or for patients with Stage IIIA disease.
  • The disease-specific survival and disease-free survival rates did not differ between the treatment groups.
  • Patients who responded to induction chemotherapy had a significantly greater 5-year OS rate (49%) than did those with stable or progressive disease (22%, p = 0.003).
  • CONCLUSION: Postoperative RT in patients with Stage IIIA NSCLC treated with induction chemotherapy followed by surgery significantly improved LC without improving OS.
  • Significantly improved survival was observed in all patients who responded to induction chemotherapy compared with those with stable or progressive disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12788166.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Yilmaz A, Sulu E, Arinç S, Saltürk C, Okur E, Aksoy F, Halezeroğlu S: Pleomorphic carcinoma of the lung: a report of six cases. Tuberk Toraks; 2007;55(3):290-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic carcinoma of the lung: a report of six cases.
  • We presented six patients with pleomorphic carcinoma of the lung.
  • The diagnosis of pleomorphic carcinoma was established with cutting needle biopsy in one case and with thoracotomy in five cases.
  • Epithelial component was squamous cell carcinoma in three cases and adenocarcinoma in the other three cases.
  • She received chemotherapy and died two months after therapy.
  • Among five patients who underwent surgery, pathologic staging was Stage IB in two patients, Stage IIB in two patients and Stage IV in one patient.
  • Treatment modality was lobectomy in three cases and pneumonectomy in two cases.
  • Survival time for patients after surgery was 2 to 20 months.
  • In conclusion, pleomorphic carcinoma is a rare tumor of the lung.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978928.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


11. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer; 2009 Apr;64(1):71-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma.
  • The prognostic relevance of blood vessel invasion (BVI) in non-small cell lung carcinoma (NSCLC) remains controversial, as is the question of whether its finding should influence therapeutic decisions after an R0 resection.
  • In all cases, lymphatic metastatic spread was at its earliest stage and only one regional lymph node was involved, 27.0+/-8.9 nodes per patient being examined histologically.
  • 62.5% were at stage IIB, 25.9% at stage IIIA, and 9.8% at stage IIA.
  • Thus 31.2% of the patients developed distant metastases by hematogenous spread (to the brain, bones, lung, adrenal, and liver, in descending order of frequency), mostly within two years of surgery.
  • Adenocarcinomas showed a strong tendency to be associated with a poorer prognosis than squamous cell carcinomas, probably because of their more frequent involvement of blood vessels.
  • The histological detection of BVI is of prognostic relevance and should be considered for inclusion in the staging criteria and indications for adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790545.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


12. Usami N, Yokoi K, Hasegawa Y, Taniguchi H, Shindo J, Yamamoto M, Suzuki R, Imaizumi K, Kondo M, Shimokata K, Central Japan Lung Study Group: Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol; 2010 Dec;15(6):583-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
  • BACKGROUND: The aim of this phase II study was to evaluate the feasibility and safety of a carboplatin and gemcitabine combination regimen in the treatment of completely resected non-small cell lung cancer (NSCLC).
  • METHODS: Patients with completely resected pathologically documented stage IB, II or IIIA NSCLC were treated with carboplatin and gemcitabine.
  • Chemotherapy consisted of 4 cycles of carboplatin at an area under the curve of 5 (level 1) or 4 (level 2) on day 1 combined with gemcitabine 1,000 mg/m(2) on days 1 and 8 every 3 weeks.
  • RESULTS: Twenty patients were treated, and the patient's demographics were: median age 61 years (range 51-74), gender male (n = 13, 65%)/female (n = 7, 35%), stage IB (n = 8, 40%), IIA (n = 1, 5%), IIB (n = 6, 30%), IIIA (n = 5, 25%).
  • Seventeen patients (85%, 95% confidence interval 64.0-94.8) received the planned 4 cycles of the chemotherapy regimen at level 1 every 3 weeks.
  • CONCLUSIONS: Adjuvant chemotherapy with a carboplatin and gemcitabine combination regimen has an acceptable toxicity profile, and the majority of patients completed 4 cycles of therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2007 Oct;30(5):498-502 [17921710.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3552-9 [18506026.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):69-80 [15603856.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):321-31 [12928123.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4285-91 [12409326.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):599-605 [16804877.001]
  • [Cites] Am J Clin Oncol. 2005 Oct;28(5):501-7 [16199991.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):317-23 [17079694.001]
  • [Cites] Lung Cancer. 2003 Jul;41(1):81-9 [12826316.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):719-27 [16945766.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Nephron. 1992;62(3):249-56 [1436333.001]
  • (PMID = 20714770.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Langner K, Thomas M, Klinke F, Bosse U, Heinecke A, Müller KM, Junker K: [Neoadjuvant therapy in non-small cell lung cancer. Prognostic impact of "mediastinal downstaging"]. Chirurg; 2003 Jan;74(1):42-8; discussion 49
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in non-small cell lung cancer. Prognostic impact of "mediastinal downstaging"].
  • [Transliterated title] Neoadjuvante Therapie des nichtkleinzelligen Lungenkarzinoms. Prognostische Relevanz des "mediastinalen Downstagings"
  • In the course of a prospective multicenter study, 40 (26 squamous cell and 14 adenocarcinomas) patients with stage IIIA and IIIB non-small cell lung cancer (NSCLC) were submitted to surgery after neoadjuvant radiochemotherapy.
  • Therapy-induced tumor regression was classified according to a three-step tumor regression grading system.
  • Of 26 patients with post-therapeutic N0 or N1 status, 21 revealed less than 10% vital tumor tissue in the resection specimens (regression grades IIb or III).
  • Patients with post-therapeutic N0 or N1 lymph node status were found to have a survival benefit compared to patients with N2 lymph node involvement, though this difference was not statistically significant (p=0.27).
  • Thus, therapy-induced tumor regression grading seems to be a more precise method to predict the outcome of the disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12552404.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


14. Gamaz M, Ameur S, Chaouche H, Bouzid K: A retrospective analysis to evaluate adjuvant chemotherapy after radical surgery on survival and disease recurrence in patients with stage I, II, IIIA non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7360

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis to evaluate adjuvant chemotherapy after radical surgery on survival and disease recurrence in patients with stage I, II, IIIA non-small cell lung cancer (NSCLC).
  • : 7360 Background: Adjuvant chemotherapy has become a standard treatment in patients (pts) with NSCLC who have had carcinologic resection (Le Chevalier, ASCO 2003, abstr 6).
  • The aim of this retrospective study was to analyze the outcome, in terms of survival and disease recurrence, of pts with NSCLC who received adjuvant chemotherapy after radical surgery.
  • METHODS: Inclusion criteria: histologically proven NSCLC stage I-IIIA treated with carcinologic surgery, PS ≤1, and adequate hematologic, hepatic, and renal function.
  • Stage IB, IIB, and IIIA disease was noted in 7, 5, and 16 pts, respectively.
  • Histologic types were adenocarcinoma (n=11) and squamous cell carcinoma (n=17).
  • The median duration between the surgery and the onset of adjuvant chemotherapy was six weeks (range, 3-7 weeks).
  • Adjuvant chemotherapy consisted of four cycles of cisplatin (75 mg/m<sup>2</sup> d1) combined with vinblastine (6 mg/m<sup>2</sup> d1) in 2 pts, vindesine (4 mg/m<sup>2</sup> d1) in 5 pts, etoposide (150 mg/m<sup>2</sup> d1) in 7 pts, and gemcitabine (1250 mg/m<sup>2</sup> over 30 min d1,8) in 14 pts.
  • Eleven pts (with p N1 disease) received locoregional radiotherapy six weeks after the fourth cycle of chemotherapy.
  • After a median follow-up time of 28 months (range, 12-44 months), the median survival was 18 months (range, 6-43+ months).
  • The median free survival time was 16 months (range, 3-40+ months).
  • CONCLUSIONS: The results of this retrospective analysis confirm the importance of adjuvant chemotherapy in NSCLC after carcinologic resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015086.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • : 7562 Background: Carboplatin plus paclitaxel and carboplatin plus gemcitabine chemotherapy have shown a good response and an improved survival against advanced NSCLC.
  • This phase II trial assessed the feasibility, safety and efficacy of a bi-weekly schedule for adjuvant chemotherapy.
  • METHODS: Patients with completely resected stage IB-IIIB NSCLC were randomized to either carboplatin (AUC3) plus paclitaxel (90mg/m2) (arm A) or carboplatin (AUC3) plus gemcitabine (1000 mg/m2) (arm B), q2w for 8 cycles within 8 weeks after surgery.
  • The main inclusion criteria were no prior chemotherapy or radiotherapy, ECOG PS 0-1, an age of less than 80 years, and an adequate organ function.
  • The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage.
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).
  • The pathological stages were IB/IIA/IIB/IIIA/IIIB: 22/10/13/29/1.
  • No treatment related deaths were observed.
  • CONCLUSIONS: This adjuvant bi- weekly scheduled chemotherapy in both arms resulted in a good compliance and feasible with acceptable levels of toxicity in completely resected NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Toyooka S, Hotta K, Nakamura H, Nakata M, Tada H, Yamashita M, Watanabe N, Sakamoto J, Aoe M, Date H: A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses. J Clin Oncol; 2009 May 20;27(15_suppl):7560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses.
  • : 7560 Background: Recent studies have demonstrated that adjuvant chemotherapy provides a survival benefit in patients with resected NSCLC.
  • In Japan, uracil-tegafur has been recognized as a standard adjuvant strategy for resected NSCLC, however, carboplatin based adjuvant chemotherapy has not been fully evaluated for the treatment of NSCLC patients in an adjuvant setting.
  • The present phase III study assessed the efficacy and safety of carboplatin/paclitaxel and oral uracil-tegafur as the first study to compare intravenous and oral drugs in resected stage IB-IIIA NSCLC.
  • METHODS: The patients with pathological stage IB-IIIA NSCLC who underwent complete resection were randomized 1:1 to carboplatin (AUC 5) /paclitaxel (175 mg/m<sup>2</sup>) every 3 week for 4 cycles (A arm) or uracil-tegafur (250 mg/m<sup>2</sup>) daily for 2 years (B arm).
  • Randomization was stratified by histology and tumor stage.
  • Sixty patients had adenocarcinoma, 30 had squamous cell carcinoma, and 10 had other histologies.
  • Disease stage was IB in 53, IIA in 14, IIB in 19, and IIIA in 14 patients.
  • Toxicities observed during adjuvant chemotherapy were well tolerable.
  • The median survival time of A and B arms combined was 4.1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963337.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Choi JH, Kim HC, Lim HY, Nam DK, Kim HS, Yi JW, Chun M, Oh YT, Kang S, Park KJ, Hwang SC, Lee YH, Hahn MH: Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer; 2001 Aug-Sep;33(2-3):171-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts.
  • Increased expression of VEGF may be associated with advanced stage and poor prognosis in patients with non-small cell lung cancer (NSCLC).
  • METHODS: Using enzyme-linked immunosorbent assay, the levels of VEGF were determined in serum from 41 patients with untreated NSCLC (Stage: IIB, 3; IIIA, 6; IIIB, 17; IV, 15; HISTOLOGY: squamous cell carcinoma, 18; adenocarcinoma.
  • There were no significant associations between the serum VEGF levels and various clinicopathologic characteristics including age, gender, histologic type, stage and treatment.
  • In seven patients with measurement of follow-up serum VEGF levels at the end of treatment (chemotherapy and/or radiotherapy), the median serum VEGF level significantly decreased after the treatment (416 pg/ml; range, 96-812 pg/ml vs. 185 pg/ml; range, 49-487 pg/ml; P=0.028).
  • However, the median platelet count (317,000/microl; range, 190,000-395,000/microl vs. 246,000/microl; range, 72,000-271,000/microl; P=0.028) and leukocyte count (10,000/microl; range, 8700-17,200/microl vs. 5100/microl; range, 3900-9500/microl; P=0.018) also decreased after the treatment.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Endothelial Growth Factors / blood. Leukocyte Count. Lung Neoplasms / blood. Lymphokines / blood. Platelet Count

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11551412.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


18. Iwazawa T, Matsui S, Ohnishi T, Kanoh T, Kimura Y, Tono T, Nakano Y, Yano H, Nakamura S, Monden T: [Two cases of recurrent lung cancer successfully treated with concurrent radiochemotherapy with vinorelbine plus cisplatin]. Gan To Kagaku Ryoho; 2004 Oct;31(10):1543-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of recurrent lung cancer successfully treated with concurrent radiochemotherapy with vinorelbine plus cisplatin].
  • Case 1:A 62-year-old man, who had undergone right upper lobectomy for lung squamous cell carcinoma (pT2pN2M0, stage IIA) 4 months earlier, was diagnosed as mediastinal lymph node recurrence by chest CT.
  • Case 2: A 63-year-old woman, who had undergone right middle-lower lobectomy for lung squamous cell carcinoma (pT2pN1M0, stage IIB) 16 months earlier, was diagnosed as hilar lymph node recurrence by chest CT.
  • Both patients underwent radiochemotherapy with 2 cycles of cisplatin (CDDP) 80 mg/m2 on day 1 and vinorelbine (VNR) 15 mg/m2 on day 1 and another day (day 8-16), and concurrent radiation (60 Gy/30 fr) for mediastinum.
  • After this treatment, a partial response (PR) in case 1 and a complete response (CR) in case 2 were achieved, and neither patient showed any relapse after 3 years of the treatment.
  • Concurrent radiochemotherapy with cisplatin and vinorelbine is considered effective without serious side effects for postoperative recurrence in localized mediastinal lymph nodes of non-small-cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lymph Nodes / pathology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508447.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


19. Ishiyama T, Aoyama T, Hirahara H, Iwashima A, Tsukada H, Souma T: [Successful resection of endotracheal metastatic lung cancer using percutaneous cardiopulmonary support system: a case report]. Kyobu Geka; 2001 Jan;54(1):19-23
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful resection of endotracheal metastatic lung cancer using percutaneous cardiopulmonary support system: a case report].
  • We experienced a rare case of endotracheal metastasis derived from squamous cell lung cancer.
  • The patient was 56 year-old male whose primary lung cancer of the left upper lobe was completely resected.
  • Pathological diagnosis indicated stage IIB and he underwent two cycles of chemotherapy with CDDP + VDS.
  • Bronchofiberoptic examination showed same as CT finding and its brushing cytology confirmed squamous cell carcinoma.
  • Majority of the reported cases of endotracheal metastases were treated conservatively as radiation, laser and/or chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cardiopulmonary Bypass / methods. Trachea / surgery. Tracheal Neoplasms / secondary. Tracheal Neoplasms / surgery
  • [MeSH-minor] Humans. Lung Neoplasms / pathology. Male. Middle Aged. Reconstructive Surgical Procedures. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11197904.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


20. Zarogoulidis K, Kontakiotis T, Hatziapostolou P, Fachantidou E, Delis D, Goutsikas J, Constantinidis TC, Athanasiadis A, Patakas D: A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer; 2001 Jun;32(3):281-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
  • We investigated the efficacy of docetaxel (D) in combination with carboplatin (C) in the treatment of non-small cell lung cancer (NSCLC) patients.
  • Of those, 46 patients had squamous carcinoma, 44 adenocarcinoma, 11 large cell carcinoma and 19 undifferentiated tumours.
  • A total of 622 cycles of chemotherapy (CHT) (median 7 (95% CI 6.2-7.47), courses per patient) were administered.
  • The median survival was 12 months for all patients, 12 for the four patients with stage IIb disease, 18 for the patients with stage IIIa disease, 20 for the 29 patients with stage IIIb disease, and 11 for the 65 stage IV patients.
  • The median time to progression was 8 months (90 patients).
  • Responders received radiotherapy (total dose, 50 Gy in 4 weeks) between the 6th and 8th cycle.
  • Among responders with initial stage IIIb disease, 7 (5%) underwent surgical resection.
  • Preliminary results indicate that the D/C combination is very active in the treatment of NSCLC with tolerable toxicity.
  • It appears that this drug combination is also good as neoadjuvant therapy in inoperable NSCLC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Carboplatin / administration & dosage. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neutropenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11390009.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Parente B, Queiroga H, Teixeira E, Sotto-Mayor R, Barata F, Sousa A, Melo MJ, João F, Neveda R, Cunha J, Fernandes A, Manuel M, Cardoso T, Ferreira L, Nogueira F, Duarte J, Semedo E, Brito U, Pimentel F, Barros S, Costa F, Almodôvar T, Araújo A: [Epidemiological study of lung cancer in Portugal (2000/2002)]. Rev Port Pneumol; 2007 Mar-Apr;13(2):255-65
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological study of lung cancer in Portugal (2000/2002)].
  • [Transliterated title] Estudo epidemiológico do cancro do pulmão em Portugal nos anos de 2000/2002.
  • Lung cancer is the most common form of cancer death in the world.
  • It is the 3rd most prevalent type of cancer in Portugal and the primary cause of cancer death.
  • 85% of lung cancer cases are attributable to smoking.
  • One study performed in Portugal for 3 years (2000/2002) by the Lung Oncology Work Committee of the Portuguese Society of Pulmonology in 22 Hospitals showed that of a total of 4396 patients with lung cancer, 81.8% were male and 18.2% were female, with a mean age of 64.49 +/- 11.28 years.
  • Histologically, 37.5% were adenocarcinoma, followed by squamous carcinoma in 30.5% of cases, and small cell lung cancer in 12.5%; neuroendocrine carcinoma presented in 1.4% of cases; non small cell lung cancer in 10.5%; mixed carcinoma in 0.7%; large cell carcinoma in 2.3%; and others/not specified in 4.6% of cases.
  • Staging (known in 4097 patients), showed 113 patients in stage IA (2.8%)and 250 patients in stage IB (6.1%); only 0.8% in stage IIA and 4.5% in stage IIB; 9.1% in stage IIIA and 29.9% in stage IIIB; 46.9% were already in stage IV by the time of diagnosis.
  • The first therapeutic option was known in 3855 patients.
  • Surgery was performed in 8.2% and 21.8% of cases were treated with combined therapies (surgery and chemotherapy or radiotherapy, or combination of chemotherapy and radiotherapy); chemotherapy alone was first choice in 43.7% of patients and in 20.3% only best support therapy was chosen.
  • [MeSH-major] Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571453.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


22. Choi NC, Fischman AJ, Niemierko A, Ryu JS, Lynch T, Wain J, Wright C, Fidias P, Mathisen D: Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2002 Nov 15;54(4):1024-35
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
  • PURPOSE: To determine the dose-response relationship between the probability of tumor control on the basis of pathologic tumor response (pTCP) and the residual metabolic rate of glucose (MRglc) in response to preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer and to define the level of residual MRglc that corresponds to pTCP 50% and pTCP > or = 95%.
  • METHODS AND MATERIALS: Quantitative dynamic 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography was performed to measure regional MRglc at the primary lesion before and 2 weeks after preoperative chemoradiotherapy in an initial group of 13 patients with locally advanced NSCLC.
  • A simplified kinetic method was developed subsequently from the initial dynamic study and used in the subsequent 16 patients.
  • The preoperative radiotherapy programs consisted of (1) a split course of 42 Gy in 28 fractions within a period of 28 days using a twice-daily treatment schedule for Stage IIIA(N2) NSCLC (n = 18) and (2) standard once-daily radiation schedule of 45-63 Gy in 25-35 fractions during a 5-7-week period (n = 11).
  • The preoperative chemotherapy regimens included two cycles of cisplatin, vinblastine, and 5-fluorouracil (n = 24), cisplatin and etoposide (n = 2), and cisplatin, Taxol, and 5-fluorouracil (n = 3).
  • The tumor histologic types included squamous cell carcinoma (n = 9), adenocarcinoma (n = 13), large cell carcinoma (n = 6), and poorly differentiated carcinoma (n = 2).
  • The extent of the primary and nodal disease was as follows: Stage IIB (T3N0M0), Pancoast tumor (n = 2); Stage IIIA, T2-T3N2M0 (n = 18); Stage IIIB: T1-T3N3M0 (n = 5) and T4N0M0 (n = 2); a second lesion, T1 (n = 1); and localized stump recurrence (n = 2).
  • Residual MRglc of 0.076 and < or = 0.040 micromol/min/g, representing pTCP 50% and pTCP > or = 95%, respectively, may be useful surrogate markers for the tumor response to radiotherapy or chemoradiotherapy in lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Fluorodeoxyglucose F18. Glucose / metabolism. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Probability. Tomography, Emission-Computed


23. Yamamoto G, Shimada T, Nishida T, Ishida Y, Iba T, Nakata T, Ohtsuki T, Takigami K, Yamaguchi Y, Yoshitake K, Tanaka A, Tsuda Y: [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers]. Gan To Kagaku Ryoho; 2001 Aug;28(8):1111-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a combination chemotherapy with nedaplatin and 5-FU for oral cancers].
  • Nedaplatin (cis-diammine-glycolato platinum: CDGP) is a platinum compound with a molecular weight of 303.18 that was recently developed in Japan.
  • There have been reports of the antineoplastic effects of Nedaplatin on cancers in the cranio-cervical region, lung, esophagus, urinary bladder, testis, ovary, and uterus.
  • In this study, we performed combined therapy of CDGP and fluorouracil (5-FU) for 8 patients with oral cancers, and evaluated the results to elucidate the clinical effect and adverse side effects.
  • The subjects were 8 patients with squamous cell carcinoma (5 males and 3 females aged 33-65 years).
  • The primary carcinoma regions were the tongue in 5 patients, oral floor in 2 patients, and mandibular gingiva in 1 patient.
  • The T-classification was T2 in 6 patients and T4 in 2 patients, and the clinical staging was Stage II in 5 patients, Stage III in 1 patient and Stage IV in 2 patients.
  • One patient was Grade IIA, 5 patients Grade IIB, and 2 patients Grade III.
  • Although the oral cancers in this study were extroverted superficial ulcerative cancers, and the number of patients was low at 8, this combined therapy is considered useful and worth evaluating in further accumulated cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Remission Induction

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, Fossella FV, Chasen M, Delclos ME, Cox JD: Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys; 2000 Sep 1;48(2):347-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Superior sulcus tumors (SST) of the lung are uncommon and constitute approximately 3% of non-small cell lung cancer (NSCLC).
  • Prognostic factors and most effective treatments are controversial.
  • In this study, we examine the 5-year survival rate by pretreatment tumor and patient characteristics and by the treatments received.
  • 03), or vertebral body (p = 0.05) involvement, stage of the disease (p < 0.01), and surgical treatment (p < 0.01).
  • Five-year survival for patients with Stage IIB disease was 47% compared to 14% for Stage IIIA, and 16% for Stage IIIB.
  • For patients with Stage IIB disease, surgical treatment (p < 0.01) and weight loss (p = 0.01) were significant independent predictors of 5-year survival.
  • Among patients with Stage IIIA disease, the only predictor of survival was Karnofsky performance score (KPS) (p = 0.02).
  • For patients with Stage IIIB disease, the only independent predictor of survival was a right superior sulcus location, which was associated with a worse 5-year survival rate than that for patients with tumors in the left superior sulcus (p = 0.02).
  • More patients with adenocarcinoma than with squamous cell tumors experienced cerebral metastases within 5 years (p < 0.01).
  • Patients without gross residual disease after surgical resection who received postoperative radiation therapy with total doses of 55 to 64 Gy had a 5-year survival rate of 82% as compared with the 5-year survival rate of 56% in patients who received 50 to 54 Gy.
  • Of these, 4 patients (17%) received radiation therapy alone or in combination with chemotherapy without surgical resection.
  • The other 19 patients (83%) had resection combined with radiation therapy and/or chemotherapy.
  • CONCLUSIONS: The findings from this study confirm the importance of the new staging system, separating T3 N0 M0 (Stage IIB) from Stage IIIA, since there was a significant difference in the 5-year survival (p < 0.01).
  • Interestingly, there was no significant 5-year survival difference between Stage IIIA (N2) and Stage IIIB (T4 or N3).
  • Disease that is minimally invading surrounding normal structures can be resected followed by radiation therapy in doses of 55 to 64 Gy.
  • Further investigation of treatment strategies combining high-dose radiation therapy (>/=66 Gy) with chemotherapy is indicated for patients with unresectable and/or node-positive (N2) SST.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Brain Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Spinal Neoplasms / secondary. Survival Rate. Survivors. Texas. Treatment Outcome. Weight Loss

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974447.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA06294; United States / NCI NIH HHS / CA / P30CA16672; United States / NCI NIH HHS / CA / T32CA77050
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement